1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

New appointment at Greenleaf Health

 
• By Sue Sutter

Former US FDA commissioner Dr Andrew von Eschenbach has joined the regulatory consulting firm Greenleaf Health as a senior advisor. Dr von Eschenbach, a urologic oncologist and former director of the National Cancer Institute, left the FDA on January 20th. At Greenleaf he will be reunited with Patrick Ronan, the firm's founder and president, who served as Dr von Eschenbach's chief of staff at the FDA in 2005 and 2006. Mr Ronan was vice-president of regulatory policy and external affairs at Novartis before starting his own consulting firm last year.

Former US FDA commissioner Dr Andrew von Eschenbach has joined the regulatory consulting firm Greenleaf Health as a senior advisor. Dr von Eschenbach, a urologic oncologist and former director of the National Cancer Institute, left the FDA on January 20th. At Greenleaf he will be reunited with Patrick Ronan, the firm's founder and president, who served as Dr von Eschenbach's chief of staff at the FDA in 2005 and 2006. Mr Ronan was vice-president of regulatory policy and external affairs at Novartis before starting his own consulting firm last year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

More from Therapeutic Category

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.